Haoxi Health Technology Launches $80 Million At-the-Market Stock Offering
Haoxi Health Technology Ltd (NASDAQ: HAO), a Beijing-based company incorporated in the Cayman Islands, announced on Friday the launch of an at-the-market (ATM) equity offering to raise up to $80 million through the sale of its Class A ordinary shares.
According to a recent SEC filing, Haoxi Health Technology has entered into a sales agreement with Aegis Capital Corp., which will serve as the sales agent for the program. Under the arrangement, shares will be sold periodically on the NASDAQ stock exchange. The timing, amount, and pricing of the sales will be determined by Haoxi’s instructions to the sales agent.
As part of the agreement, Haoxi will pay Aegis Capital a commission equal to 2.5% of the gross proceeds from each sale made through the ATM program. Additionally, Haoxi agreed to reimburse Aegis Capital for certain expenses up to an annual cap of $75,000 and to provide customary indemnification and contribution rights to the sales agent.
This offering is being conducted pursuant to a base prospectus dated June 10, 2025, and a prospectus supplement filed on Friday. Both documents are incorporated into the company’s shelf registration statement on Form F-3, which was declared effective by the U.S. Securities and Exchange Commission on June 13, 2025. Haoxi’s CEO, Zhen Fan, signed the sales agreement on behalf of the company.
The funds raised through this ATM offering are expected to provide Haoxi Health Technology with additional capital to support its business growth and operational needs. Investors and market participants will be monitoring how the offering impacts the stock’s liquidity and market dynamics in the coming weeks.
This announcement comes amid broader market attention to equity financing activities by companies in the technology and healthcare sectors. Haoxi Health Technology specializes in health-related technologies and the offering marks its latest strategic move in capital market engagement.
For more detailed information, investors are advised to review Haoxi’s official SEC filings and public disclosures.
